319 related articles for article (PubMed ID: 19074975)
21. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
22. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
Furuta S; Smart C; Hackett A; Benning R; Warrington S
Xenobiotica; 2013 May; 43(5):432-42. PubMed ID: 23075005
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
27. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
28. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Duttaroy A; Voelker F; Merriam K; Zhang X; Ren X; Subramanian K; Hughes TE; Burkey BF
Eur J Pharmacol; 2011 Jan; 650(2-3):703-7. PubMed ID: 21070766
[TBL] [Abstract][Full Text] [Related]
29. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
30. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
[TBL] [Abstract][Full Text] [Related]
31. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.
Prakash C; Johnson KA; Gardner MJ
Drug Metab Dispos; 2008 Jul; 36(7):1218-26. PubMed ID: 18372400
[TBL] [Abstract][Full Text] [Related]
32. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
Landersdorfer CB; He YL; Jusko WJ
Br J Clin Pharmacol; 2012 Mar; 73(3):391-401. PubMed ID: 22442826
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
34. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
35. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
[TBL] [Abstract][Full Text] [Related]
36. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin.
Asakura M; Nakano M; Hayashida K; Fujii H; Nakajima M; Atsuda K; Itoh T; Fujiwara R
Drug Metab Pharmacokinet; 2014; 29(6):463-9. PubMed ID: 25008847
[TBL] [Abstract][Full Text] [Related]
37. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
38. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
[TBL] [Abstract][Full Text] [Related]
39. Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.
Asakura M; Karaki F; Fujii H; Atsuda K; Itoh T; Fujiwara R
Sci Rep; 2016 Oct; 6():35633. PubMed ID: 27759084
[TBL] [Abstract][Full Text] [Related]
40. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
